boluo613
2022-11-18
to the moon
[龇牙]
Provention Bio's type 1 diabetes med teplizumab wins FDA approval
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":667606941,"tweetId":"667606941","gmtCreate":1668739138383,"gmtModify":1668739140289,"author":{"id":3569806649777366,"idStr":"3569806649777366","authorId":3569806649777366,"authorIdStr":"3569806649777366","name":"boluo613","avatar":"https://static.tigerbbs.com/76878c45deee1566c2a4439d15dcd0b5","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":5,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>to the moon<a href=\"\">[龇牙] </a></p></body></html>","htmlText":"<html><head></head><body><p>to the moon<a href=\"\">[龇牙] </a></p></body></html>","text":"to the moon[龇牙] ","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/667606941","repostId":2284745607,"repostType":2,"repost":{"id":"2284745607","kind":"highlight","pubTimestamp":1668726089,"share":"https://www.laohu8.com/m/news/2284745607?lang=&edition=full","pubTime":"2022-11-18 07:01","market":"us","language":"en","title":"Provention Bio's type 1 diabetes med teplizumab wins FDA approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2284745607","media":"seekingalpha","summary":"The US FDA has granted approval to Provention Bio (NASDAQ:PRVB) for Tzield (teplizumab) to delay the","content":"<html><body> <ul> <li>The US FDA has granted approval to Provention Bio (<span>NASDAQ:PRVB</span>) for Tzield (teplizumab) to delay the onset of stage 3 of type 1 diabetes (T1D).</li> <li>The first-in-class medicine is given via intravenous infusion daily for 14 consecutive days.</li> <li>The therapy works by binding to specific immune system cells. It may also deactivate the immune cells that attack insulin-producing cells, while increasing the amount of cells that can moderate an immune response.</li> <li>Approval was based on the results of a placebo-controlled trial that showed over a median follow-up of 51 months, 45% of patients who received Tzield were later diagnosed with stage 3 T1D, compared to 72% of those on a placebo.</li> <li>Provention Bio (PRVB) shares soared earlier in November after the FDA issued proposed labeling for teplizumab.</li> </ul></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Provention Bio's type 1 diabetes med teplizumab wins FDA approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProvention Bio's type 1 diabetes med teplizumab wins FDA approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-11-18 07:01 GMT+8 <a href=https://seekingalpha.com/news/3909501-provention-bio-type-1-diabetes-med-teplizumab-wins-fda-approval><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The US FDA has granted approval to Provention Bio (NASDAQ:PRVB) for Tzield (teplizumab) to delay the onset of stage 3 of type 1 diabetes (T1D). The first-in-class medicine is given via intravenous ...</p>\n\n<a href=\"https://seekingalpha.com/news/3909501-provention-bio-type-1-diabetes-med-teplizumab-wins-fda-approval\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/810721154/image_810721154.jpg","relate_stocks":{"PRVB":"Provention Bio, Inc","BK4007":"制药"},"source_url":"https://seekingalpha.com/news/3909501-provention-bio-type-1-diabetes-med-teplizumab-wins-fda-approval","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2284745607","content_text":"The US FDA has granted approval to Provention Bio (NASDAQ:PRVB) for Tzield (teplizumab) to delay the onset of stage 3 of type 1 diabetes (T1D). The first-in-class medicine is given via intravenous infusion daily for 14 consecutive days. The therapy works by binding to specific immune system cells. It may also deactivate the immune cells that attack insulin-producing cells, while increasing the amount of cells that can moderate an immune response. Approval was based on the results of a placebo-controlled trial that showed over a median follow-up of 51 months, 45% of patients who received Tzield were later diagnosed with stage 3 T1D, compared to 72% of those on a placebo. Provention Bio (PRVB) shares soared earlier in November after the FDA issued proposed labeling for teplizumab.","news_type":1},"isVote":1,"tweetType":1,"viewCount":440,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":17,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/667606941"}
精彩评论